Wesbanco Bank Inc. Purchases Shares of 5,600 LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Wesbanco Bank Inc. acquired a new stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 5,600 shares of the medical instruments supplier's stock, valued at approximately $470,000.

Other hedge funds also recently modified their holdings of the company. Compass Planning Associates Inc boosted its position in LeMaitre Vascular by 91.4% in the first quarter. Compass Planning Associates Inc now owns 11,776 shares of the medical instruments supplier's stock worth $988,000 after purchasing an additional 5,623 shares during the last quarter. Vest Financial LLC bought a new position in shares of LeMaitre Vascular in the first quarter worth approximately $1,470,000. Annex Advisory Services LLC raised its stake in shares of LeMaitre Vascular by 9.2% during the first quarter. Annex Advisory Services LLC now owns 34,582 shares of the medical instruments supplier's stock valued at $2,901,000 after acquiring an additional 2,905 shares during the last quarter. Chatham Capital Group Inc. raised its holdings in shares of LeMaitre Vascular by 3.6% during the first quarter. Chatham Capital Group Inc. now owns 50,254 shares of the medical instruments supplier's stock valued at $4,216,000 after acquiring an additional 1,765 shares in the last quarter. Finally, Portside Wealth Group LLC lifted its holdings in LeMaitre Vascular by 14.3% in the first quarter. Portside Wealth Group LLC now owns 6,094 shares of the medical instruments supplier's stock worth $562,000 after buying an additional 764 shares during the period. Institutional investors and hedge funds own 84.64% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on LMAT shares. Lake Street Capital increased their price objective on shares of LeMaitre Vascular from $105.00 to $110.00 and gave the stock a "buy" rating in a research note on Friday, February 28th. Oppenheimer cut shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a report on Friday, February 28th. Barrington Research lowered shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research note on Friday, February 28th. Finally, Wells Fargo & Company began coverage on LeMaitre Vascular in a research note on Thursday, February 13th. They set an "equal weight" rating and a $95.00 target price on the stock. Five equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $97.83.

Insider Buying and Selling

In other news, CEO George W. Lemaitre sold 18,733 shares of LeMaitre Vascular stock in a transaction on Friday, May 16th. The stock was sold at an average price of $84.77, for a total value of $1,587,996.41. Following the completion of the transaction, the chief executive officer now directly owns 1,873,651 shares in the company, valued at approximately $158,829,395.27. The trade was a 0.99% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold a total of 100,000 shares of company stock valued at $8,556,857 in the last three months. Insiders own 9.50% of the company's stock.

LeMaitre Vascular Stock Down 1.2%

LMAT stock traded down $0.96 during mid-day trading on Thursday, reaching $82.18. 15,256 shares of the stock traded hands, compared to its average volume of 167,973. LeMaitre Vascular, Inc. has a 52 week low of $71.42 and a 52 week high of $109.58. The firm has a market capitalization of $1.86 billion, a PE ratio of 44.91, a P/E/G ratio of 2.22 and a beta of 0.83. The business has a 50-day moving average of $83.75 and a two-hundred day moving average of $90.64.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last issued its earnings results on Thursday, May 1st. The medical instruments supplier reported $0.48 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.02). LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The business had revenue of $59.87 million for the quarter, compared to the consensus estimate of $57.61 million. During the same quarter in the previous year, the firm posted $0.44 EPS. The business's revenue was up 12.0% on a year-over-year basis. On average, equities research analysts anticipate that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, May 29th. Investors of record on Thursday, May 15th were given a dividend of $0.20 per share. The ex-dividend date of this dividend was Thursday, May 15th. This represents a $0.80 annualized dividend and a yield of 0.97%. LeMaitre Vascular's dividend payout ratio is presently 40.40%.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.